JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $23
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $20 to $23.
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $20 to $23.